Janux Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Accounts Receivable of $149.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$34.85M.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $35.00M.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$8.00M, a 200.00% decline from fiscal 2020.
- Janux Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $8.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $149.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $35.00M 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-06-30 | $6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.50M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $519.00K 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$750.00K derived: sum of 2 quarters · filed 2024-08-07 | $0.00 10-Q · filed 2023-11-07 | -$500.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-06-30 | -$750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | -$500.00K derived: sum of 3 quarters · filed 2024-08-07 | $0.00 derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $750.00K 10-Q · filed 2024-05-08 | $250.00K derived: sum of 2 quarters · filed 2024-05-08 | $750.00K derived: sum of 3 quarters · filed 2024-05-08 | $750.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 derived: sum of 3 quarters · filed 2023-11-07 | $0.00 10-K · filed 2023-03-10 |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $500.00K derived: sum of 2 quarters · filed 2023-11-07 | $500.00K 10-Q · filed 2023-11-07 | $500.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-05-09 | -$375.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | -$375.00K derived: sum of 3 quarters · filed 2023-05-09 | -$375.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$375.00K derived: sum of 2 quarters · filed 2023-03-10 | -$375.00K derived: sum of 3 quarters · filed 2023-03-10 | -$8.00M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$375.00K derived: sum of 2 quarters · filed 2022-11-10 | -$8.00M 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$7.63M 10-Q · filed 2022-08-09 | $375.00K derived: sum of 3 quarters · filed 2022-08-09 | $375.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$7.63M 10-Q · filed 2022-05-10 | $375.00K derived: sum of 2 quarters · filed 2022-05-10 | $375.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $8.00M derived: sum of 2 quarters · filed 2022-03-18 | $8.00M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |